|

Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC

RECRUITINGSponsored by Guangdong Provincial People's Hospital
Actively Recruiting
SponsorGuangdong Provincial People's Hospital
Started2025-02-01
Est. completion2025-12-01
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06771960

Summary

EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age 18-80 years old;
* Pathologically diagnosed EGFR-mutated non-small cell lung cancer (NSCLC);
* Treated with neoadjuvant targeted therapy;
* Undergoing definitive surgery.

Exclusion Criteria:

* A history of prior chemotherapy, immunotherapy, or radiotherapy.
* A history of malignancy or lung surgery;
* Missing key data.

Conditions3

CancerLung CancerLung Cancer (NSCLC)

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.